Tumor angiogenesis is crucial for sustained development of solid tumors, and vascular-targeting strategies for mesothelioma are showing promise (4), including use of Bevacizumab (also referred to as Avastin), an anti-vascular endothelial growth factor (VEGF)A antibody combined with cisplatin and pemetrexed (4, 5). Here, VEGFA is linked to neoplasm.